Close
Digital Health & Ai Innovation summit 2026
Medical Taiwan 2026

LabCorp Receives Authorization for COVID-19 Sample Pooling

Asia Pacific countries fast track review processes benefits Clinical Trial clients

LabCorp, a leading global life sciences company that is deeply integrated in guiding patient care, announced it received an EUA from the U.S. FDA permitting diagnostic testing of groups of individuals for active COVID-19 infections utilizing matrixed pooled testing, a method that tests several patient samples at once.

LabCorp’s unique matrixed pooled strategy for COVID-19 provides an efficient testing approach for populations by allowing for larger groups of samples to be tested at one time. This methodology can quickly provide quality test results for individuals within the group, without requiring retesting in the majority of cases. Pooled testing may be used for populations at low risk of COVID-19, when testing demand exceeds laboratory capacity, or when testing reagents are in short supply.

“We believe science and technology are the best ways to beat the virus, and our matrixed pooled testing method is another way LabCorp is helping to respond to this health crisis,” said Brian Caveney, chief medical officer and president of LabCorp Diagnostics. “Pooling methods test groups of individuals efficiently and with high quality, while increasing our overall testing capacity. The demand for testing continues to increase and we are committed to finding innovative solutions to ensure testing is available.”

LabCorp’s matrixed pooled testing method involves testing up to five samples at once. If there is a positive sample in the pool, LabCorp can identify the individual positive sample in the pool using patterns detected by its robotic testing platform. Pooled testing can reduce the number of tests required in specific populations, optimize laboratory testing supplies, and increase testing capacity.

LabCorp received the EUA from the FDA on July 24 for the qualitative detection of nucleic acid from SARS-CoV-2 in upper and lower respiratory specimens from individuals suspected of COVID-19, using a matrix pooling strategy (i.e., group pooling strategy), containing up to five individual upper respiratory swab specimens (nasopharyngeal, mid-turbinate, anterior nares or oropharyngeal swabs) per pool and 25 specimens per matrix, where each specimen is collected under observation or by a healthcare provider using individual vials containing transport media. Negative results from pooled testing should not be treated as definitive. If a patient’s clinical signs and symptoms are inconsistent with a negative result or results are necessary for patient management, then the patient should be considered for individual testing. Specimens included in pools where the positive sample cannot be identified using the matrix must be tested individually prior to reporting a result. Specimens with low viral loads may not be detected in sample pools due to decreased sensitivity of pooled testing.

LabCorp’s COVID-19 molecular test has been authorized by the FDA under an EUA only for the detection of nucleic acid from SARS-CoV-2, and not for any other viruses or pathogens, and has not been FDA cleared or approved. The test is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostic tests for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

This EUA is effective until the declaration that circumstances exist justifying the authorization of the emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 is terminated under Section 564(b)(2) of the Act or the EUA is revoked under Section 564(g) of the Act.

About LabCorp

LabCorp, an S&P 500 company, is a leading global life sciences company that is deeply integrated in guiding patient care, providing comprehensive clinical laboratory and end-to-end drug development services. With a mission to improve health and improve lives, LabCorp delivers world-class diagnostics solutions, brings innovative medicines to patients faster, and uses technology to improve the delivery of care. LabCorp reported revenue of more than $11.5 billion in 2019.

ALRT Launches Prediabetes Solution Completing Most Comprehensive Diabetes Management System Available Today

ALR Technologies Inc. is launching the ALRT Prediabetes Solution. This is a new, prevention-based feature of the ALRT Diabetes Solution that is already well-positioned in the diabetes patient care marketplace. The new product was designed in direct response to discussions with government healthcare authorities for a scalable solution that could address the growing problem of prediabetes.

ALRT is making its new Prediabetes Solution available at no cost to health plans that are using the ALRT Diabetes Solution for their current beneficiaries who have diabetes. This will help payer groups manage the diabetes pandemic at its most treatable stage.

The newest features expand the scope of the ALRT Diabetes Solution, further cementing it as the most comprehensive diabetes management platform available on the market today. The Prediabetes Solution provides patients with educational videos and supplemental content formatted for mobile devices and a private online community to discuss disease management (e.g., support, weight loss, diet, etc.). Most importantly, the System tracks patients and reminds them to test their A1C according to payer protocols. This is the best way to ensure that patients get therapy as soon as they cross the threshold to overt diabetes. Effectively, the ALRT Prediabetes Solution gives patients access to all the products in the ALRT Diabetes Solution, less the blood glucose testing supplies and weekly reviews by the healthcare team.

“In our discussions with government healthcare authorities, we became acutely aware of their desire for turnkey technology that addresses both diabetes and prediabetes,” commented Sidney Chan, CEO of ALR Technologies. “Ultimately, most people with prediabetes will transition into diabetes, which is when costs start skyrocketing and quality of life diminishes. Our goal is to provide solutions that can delay, or even prevent, the onset of full-on disease, while getting patients and healthcare providers into the ALRT Diabetes Solution framework.”

The ALRT Prediabetes system will give patients the tools that they need to be proactive in monitoring their A1C. As with any disease, early detection is critical to controlling outcomes. As soon as a patient’s A1C exceeds the diagnostic threshold for diabetes, the healthcare provider can immediately prescribe the ALRT Diabetes Solution to closely monitor and guide the patient’s clinical progress.

“Prediabetes is a major concern for healthcare payers,” continued Mr. Chan. “We are now offering a turnkey prediabetes solution at no cost for both government and private health plans to aid in diabetes detection. This will help reduce treatment costs and hopefully result in slowing the accelerating diagnosis rate for diabetes, one of the most expensive chronic diseases in the world.”

“The ALRT blood glucose testing system uses one of the most accurate monitors available, yet it will cost less than most other testing platforms. For health plans that purchase the ALRT blood glucose testing system, the management system for Diabetes Solution and Prediabetes Solution will be available at no cost,” concluded Mr. Chan.

About ALR Technologies Inc.

ALR Technologies is a medical device company that developed the ALRT Diabetes Solution, a comprehensive approach to diabetes care that includes: an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices; a patent pending Predictive A1C algorithm to track treatment success between lab reports and an FDA-cleared Insulin Dosing Adjustment program. ALRT also offers an algorithm to provide prescribers support for timely non-insulin medication advancements. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes. The program tracks performance of all clinical activities to ensure best practices are followed. The ALRT Diabetes Solution gives providers a platform for remote diabetes care, helping to minimize patient exposure to potential infections in clinical settings. Currently, the Company is focused on diabetes and will expand its services to cover other chronic diseases anchored on verifiable data.

Masimo Expands the Masimo SafetyNet Remote Patient Management Solution with Continuous Body Temperature Measurement

Masimo announced a significant expansion to the Masimo SafetyNet™ platform with the introduction of Radius T°™, a wearable, wireless sensor that provides continuous body temperature measurements. By augmenting the already powerful Masimo SafetyNet, which features Radius PPG™ tetherless pulse oximetry, with Radius T°, the remote patient management solution becomes capable of tracking four key vital signs – oxygen saturation, respiration rate, pulse rate, and now temperature – making it an ideal solution for assessing the status of patients with suspected or low-acuity COVID-19, among many other remote patient management uses. Unlike spot-check thermometry solutions, Radius T° measures body temperature continuously, providing remote notifications when a patient’s temperature is outside a clinician-specified range – giving peace of mind to caregiver and patient alike.

Masimo SafetyNet uses a tetherless, wearable single-patient-use Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry sensor to monitor a patient’s blood oxygen saturation and pulse rate, as well as respiration rate, perfusion index, and PVi®. Masimo SafetyNet is designed to help manage the surge in COVID-19 patients while maintaining distance from other patients and providers, allowing hospitals to expand remote patient monitoring into alternative care spaces, including overflow locations, emergency recovery facilities, and home care settings. The telehealth platform combines tetherless pulse oximetry—and now also Radius T° continuous temperature measurement – with a cloud-based remote data capture and surveillance platform accessible from a patient’s Android or iOS smartphone or smart device. Monitoring key physiological data provides clinicians with the ability to assess patient status and facilitates awareness of the need for intervention.

Temperature measurement by patients at home typically occurs intermittently, at the prompting of a clinician, and is prone to poor compliance in the collection and reporting of data to healthcare providers in a timely, consistent fashion. A patient taking their temperature at regular or semi-regular intervals may only notice a spike in temperature hours after a fever has begun, or may not even be aware of it, delaying possible clinical intervention. In contrast, Radius T° collects data continuously and seamlessly, recording trend data and automatically notifying remotely when a clinician-specified high temperature threshold is breached, without any action needed on the patient’s part. By eliminating inconsistent manual measurements and concerns about patient compliance, while providing continuous insight into changes in body temperature, Radius T° is intended to significantly improve patient status assessment workflows.

Radius Tº is small, light, and comfortable, and is easily applied to the chest. Each shower-proof, single-patient-use sensor lasts up to 8 days and can be worn throughout the day and night, allowing patients to continue normal daily activities while still being monitored. Applied to the skin, Radius T° uses proprietary algorithms to measure the patient’s body temperature, not just external skin temperature, with laboratory accuracy within ±0.1ºC, whereas other thermometry solutions typically have laboratory accuracy within ±0.2ºC. Using Bluetooth&reg, Radius T° provides this continuous data to the Masimo SafetyNet app on the patient’s smartphone and via secure cloud to clinicians back at the hospital, allowing them to track and trend a patient’s body temperature, helping them to spot potential deterioration in patient status using the web-based Masimo SafetyNet Clinician Portal.

Joe Kiani, Founder and CEO of Masimo, said, “We’re proud to add this noninvasive, continuous, wearable thermometer solution to our growing family of remote patient management solutions. Masimo SafetyNet has already helped clinicians effectively care for countless patients during the pandemic. With the addition of Radius T°, Masimo SafetyNet becomes an even more useful tool for remotely managing patients with COVID-19 and many other health concerns.”

Radius T° is indicated for use on patients 5 years and older. Radius T° is not FDA 510(k) cleared; the device is marketed under the FDA’s Enforcement Policy for Clinical Electronic Thermometers During COVID-19.

About Masimo
Masimo is a global medical technology company that develops and produces a wide array of industry-leading monitoring technologies, including innovative measurements, sensors, patient monitors, and automation and connectivity solutions. Our mission is to improve patient outcomes and reduce the cost of care. Masimo SET® Measure-through Motion and Low Perfusion™ pulse oximetry, introduced in 1995, has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.

Philips integrating masimo measurement tech into select patient monitors

Masimo and Royal Philips, both global leaders in patient monitoring, announced that they have reinforced their partnership, whereby Philips will integrate additional Masimo measurement technologies into select IntelliVue MX-series multi-parameter monitors, to help clinicians assess cerebral oximetry and ventilation status.

Core Masimo noninvasive measurements, such as SET Measure-through Motion and Low Perfusion pulse oximetry and advanced rainbow SET Pulse CO-Oximetry parameters like noninvasive hemoglobin (SpHb), have long been available on a wide range of Philips multi-parameter monitors.In 2016, Masimo and Philips entered into a multi-year business partnership involving both companies’ innovations in patient monitoring and therapy solutions. Now, in 2020, Philips becomes one of Masimo’s first industry partners to launch additional advanced Masimo measurements, NomoLine and O3, in their own patient monitors, sharing Masimo’s expertise in capnography and regional cerebral oximetry with caregivers and patients around the world.

NomoLine capnography and O3 regional oximetry measurements are available now on Philips MX500 and MX550 monitors1 in select markets2 throughout the world, and are also available directly from Masimo on its Root Patient Monitoring and Connectivity Platform and when connected to select Philips patient monitors via Philips’ IntelliBridge module:

NomoLine “no-moisture” sampling lines are designed for low-flow applications and can be used in a variety of clinical scenarios and care settings, on both intubated and non-intubated patients of all ages, in both low- and high-humidity applications.
O3 regional oximetry may help clinicians monitor cerebral oxygenation in situations in which pulse oximetry alone may not be fully indicative of the oxygen in the brain.

“As global leader in health technology, we are delighted to reinforce our partnership with Masimo, bringing their advanced measurements to our innovative IntelliVue patient monitors, thereby making them even more versatile,” said Frans van Houten, CEO of Royal Philips. “Our customers expect integrated solutions to help them address the quadruple aim of healthcare. The complementary strengths of Philips and Masimo allow us to offer, reliable ventilation and regional oximetry solutions, which we expect will help clinicians deliver even better patient care.”

“Combining our expertise in noninvasive monitoring and signal processing technologies with Philips’ expertise in integrated patient monitoring and therapy solutions is a win-win for patients and clinicians alike,” said Joe Kiani, Founder and CEO of Masimo. “We are proud that Philips, recognizing our expertise in this clinical space, has chosen to make our innovative O3 and NomoLine platforms available to their customers. We look forward to continuing our partnership with a focus on improving patient outcomes and reducing the cost of care.” –MPO

Thermo Fisher Scientific strengthens its global response to COVID-19

Thermo Fisher Scientific strengthens its global response to COVID-19

Thermo Fisher Scientific continues to expand global capacity and capabilities across its leading pharma services network to support customers in government, industry and academia as they accelerate development and production of COVID-19 vaccines, therapies and other treatments. The company is now supporting over 200 projects globally.

“Even before the pandemic, the company was strategically increasing its manufacturing, research and development capabilities, in addition to providing critical products and solutions for treating cancer, genetic diseases and other serious health concerns. Today, these initiatives are proving to be decisive in enabling our response to COVID-19 in India. We are well-positioned to extend our end-to-end workflow solutions for COVID-19 and quickly ramp up testing infrastructure and vaccine research and manufacturing,” said Amit Chopra, managing director, India & Middle East, Thermo Fisher Scientific.

Thermo Fisher is also supporting multiple vaccine programs globally that are in or entering human clinical trials, providing critical capacity and expertise that has accelerated development and readiness by months.

“Our investments in building capacity and capabilities demonstrate our commitment to fulfill our mission to enable our customers to make the world healthier, cleaner and safer,” Amit added.

The company has expanded capacity for customers who are developing new and existing therapies, including promising anti-viral drugs, to meet increased demand and enable biopharma customers to significantly compress timelines for delivery to patients.

In addition to its work on COVID-19-related vaccines and therapies, the company continues to ensure that patients undergoing clinical trials continue to receive the critical medicines they need. A “site to patient” program, launched at the start of the pandemic, has ensured clinical trial patients have uninterrupted access to life-saving investigational drug shipments without having to visit a clinic, one of many efforts to maintain supply chain continuity during the pandemic. – MB Bureau

Emirates Hospitals Group Embraces Digital Transformation Using Okadoc’s Advanced Technology, Based on InterSystems

Emirates Hospitals Group Embraces Digital Transformation Using Okadoc's Advanced Technology, Based on InterSystems

Emirates Hospitals Group (EHG), one of the largest private healthcare providers in the region, has successfully achieved another milestone in digitizing its health care services by implementing Okadoc’s white label booking and telemedicine solution.

Responding quickly to the increased need for telehealth solutions as a consequence of COVID-19, EHG successfully implemented the Okadoc solution in line with its digitization goals; leveraging Okadoc’s innovative booking and telemedicine platform to transform health care delivery and patient management.

All patients can now conveniently schedule and manage their appointments via the hospital’s website. Okadoc’s solution also allows patients who previously made appointments through EHG’s call centers to manage their bookings online.

Okadoc’s white label solution is directly integrated with EHG’s healthcare information system, InterSystems TrakCare®, allowing patients to view doctor’s availability in real-time to schedule and manage appointments 24/7 with no downtime. After patient bookings are made, an automatically generated confirmation and booking reminder is sent to the patients enabling them to connect online to access the information they need easily and effectively. Okadoc’s solution will reduce no shows and optimize bookings, increasing EHG’s revenues and reducing operational costs especially those associated with maintaining a call center for appointment scheduling.

The platform further allows patients to use chat and video calls with their doctors any time of day, transfer and receive documents such as prescriptions and medical records and pay for their consultations without delays. The safe and secure system ensures all patient data remains confidential.

“Okadoc’s cloud-based booking and telemedicine platform is designed to help patients and doctors connect easily and seamlessly. In these current times, when patients are more comfortable booking consultations from the convenience of their own homes, our partnership with Emirates Hospitals Group and integration with InterSystems allowed EHG to quickly extend Okadoc’s offerings under their own brand” said Fodhil Benturquia, Founder & CEO, Okadoc.

With EHG’s online booking platform also connected to InterSystems TrakCare unified healthcare information system, the group has digitized its services giving patients access to doctors’ real-time availability from their mobile applications and the EHG website.
TrakCare also provides EHG with a holistic view of each patient’s clinical, administrative, and financial information at any given time on any authorized internet-connected device.

“At Emirates Hospital Group, we have long appreciated the importance that technology plays in providing the highest standard of care to our patients. In addition to taking us into the next stage of our digital transformation journey, our partnership with Okadoc and InterSystems has allowed us to continue the spectrum of care for our patients during this COVID-19 time with a focus on offering a seamless and secure patient journey,” said Dr. Michael Fakih, CEO of Emirates Hospitals Group.

“More than ever before, it’s important for healthcare providers to be able to adapt their technology quickly to meet the current needs of patient care. Emirates Hospital Group has always been at the forefront when it comes to digitalization and innovation in healthcare,” said Ali Abi Raad, Country Manager for the Middle East and India at InterSystems. “Together with Okadoc, InterSystems helped EHG achieve their digital transformation goals and ensure their patients continue to receive the care they need.”

Okadoc’s white label booking and telemedicine solution can be embedded easily into the healthcare providers’ websites and mobile applications and can be deployed within a matter of a few hours. Okadoc’s technology is TRA (Telecommunications Regulatory Authority) approved, using end-to-end encryption with the cloud data hosted in the UAE, and compliant with UAE regulations.

About Emirates Hospitals Group
Emirates Hospital Group (EHG)is a leading healthcare provider delivering integrated healthcare services and offering primary, secondary, and tertiary care through its extensive portfolio of healthcare facilities.

It owns and operates an extensive portfolio of full-service hospitals, specialty clinics, urgent care centers, and pharmacies, with the capacity to serve over 3.3 million outpatients and 22,000 inpatients. These assets enable EHG to offer a patient-centric continuum of care. Apart from direct healthcare, EHG has also invested in centers of excellence for rehabilitation, general well-being and cosmetic services.

About Okadoc:
Okadoc is a ‘made in UAE’​ tech company that aims to improve your healthcare experience. Wherever they are, patients can use Okadoc’s app to find in-network doctors, instantly book appointments online, receive reminders for upcoming appointments and more. Okadoc’s telemedicine platform enables virtual consultations and connects patients to over 400 doctors and 30 healthcare providers across the country. Okadoc’s app is also a 24/7 intelligent medical calendar system that helps practitioners, clinics and hospitals optimize their bookings, attract and engage new patients, build and strengthen their online reputation, reduce ‘no-shows’​ and more. Okadoc’s online marketplace delivers the efficient, seamless, and simple experience that everyone expects and deserves.

About InterSystems
Established in 1978, InterSystems is the leading provider of data technology for extremely critical data in the healthcare, finance, and logistics sectors. Its cloud-first data platforms solve interoperability, speed, and scalability problems for large organizations around the globe. InterSystems also develops and supports unique managed services for hospital EMRs, unified care records for communities and nations, and laboratory information management systems. InterSystems is committed to excellence through its award-winning, 24×7 support for customers and partners in more than 80 countries. Privately held and headquartered in Cambridge, Massachusetts, InterSystems has 25 offices worldwide.

Saudi German Hospital Improves Patient Experience with AI Bots from Automation Anywhere

Saudi German Hospital Improves Patient Experience with AI Bots from Automation Anywhere

Automation Anywhere, a global leader in Robotic Process Automation (RPA), announced a collaboration with Saudi German Hospital (SGH), using AI-powered software bots to help improve patient care and automate end-to-end business processes during the COVID-19 crisis.

The digital workers provided by Automation Anywhere are expected to transform SGH front and back offices to modernize key touchpoints — from patient on-boarding to insurance billings, office management operations and other financial processes – ultimately improving business resiliency for one of the largest healthcare providers in the region. The deployment was facilitated by Advansys ESC.

“The addition of newest Automation capabilities will allow SGH hospital to add value and support caregivers in the treatment process by providing deeper insights on the patient’s specific condition, lifestyle & patient behavior in real time,” said Dr. Reem Osman – Group CEO- Saudi German Hospitals UAE. “The cognitive and AI technology infusion will empower our Intelligent Patient Platform to expand competencies and deliver better outcomes.”

The RPA implementations are expected to have a huge impact to reduce patient waiting times and improved patient experiences. Automation Anywhere and Advansys ESC worked with Saudi German Hospital to also identify automation opportunities in its insurance and finance departments that typically handle high-volume manual processes, such as insurance eligibility, insurance pre-authorization and patient enrollment.

“Intelligent automation empowers healthcare organizations to perform more time-consuming, manual tasks, freeing up staff to treat an increased number of patients by improving hospital efficiencies,” said Milan Sheth, executive vice president, IMEA at Automation Anywhere. “Medical systems impacted by the global pandemic are seeing how automation technology can have a huge impact on a patient’s progress by implementing bots for processes, such as simplifying patient appointment scheduling, streamlining account settlements and managing healthcare workflows. All of this time saved can go right back into patient care.”

About Automation Anywhere

Automation Anywhere is a global leader in Robotic Process Automation (RPA), empowering customers to automate end-to-end business processes with software bots – digital workers that perform repetitive and manual tasks, resulting in dramatic productivity gains, optimized customer experience and more engaged employees. The company offers the world’s only web-based and cloud-native intelligent automation platform combining RPA, artificial intelligence, machine learning, and analytics right out of the box, to help organizations rapidly start and scale their process automation journey. Its Bot Store is the world’s first and largest marketplace with more than 850 pre-built, intelligent automation solutions. With offices in more than 40 countries and a global network of 1,900 partners, Automation Anywhere has deployed over 1.8 million bots to support some of the world’s largest enterprises across all industries.

About Saudi German Hospital:

Saudi German Hospitals UAE is one of the largest and leading healthcare providers in the UAE with 3 tertiary care operating hospitals and 1 multidisciplinary clinic. The construction of the 150 operational beds SGH Ras Al Khaimah hospital is in progress and expected to start operation in mid of 2022. The Saudi German Centers of Excellence Dubai is in various stages of completion and scheduled to start the construction of the Batterjee Medical City Ajman. There are also different projects of Medical cities, centers of excellence and hospitals within the UAE and outside UAE under different stages of planning and execution

Abbott receives FDA approval for iOS-Compatible App for personalizing therapies for pain, Parkinson’s disease

Abbott

Abbott announced it has received approval from the U.S. FDA for the use of the company’s Patient Controller app on compatible personal Apple‡ smartphone devices. At Abbott, this approval allows patients living with neurological conditions, including chronic pain or movement disorders, the ability to manage therapy directly from their personal smartphone.2

With this app approval, the need to carry a separate patient programmer device is eliminated, streamlining the patient’s experience and seamlessly integrating therapy management into their life. This is an important step in the integration and connection of digital health tools that ultimately help patients live fuller, healthier lives.

“For physicians who are prescribing and implanting neuromodulation technologies, the ability to integrate therapies into one’s everyday life is key,” said Alexander Escobar, M.D., Clinical Assistant Professor of Anesthesiology and Pain Medicine at The University of Toledo, OH. The COVID-19 global health crisis has demanded access to virtual treatment options, especially for those individuals with chronic medical conditions that may have difficulty coming to see their physician or would prefer not to leave their own home. To ensure our patients are receiving the care they need in the appropriate setting, close follow up is critical. Physicians have the ability to remain engaged with their patients through the Apple device, allowing them to interact and treat debilitating chronic pain.”

“The ability to support the changing needs of individuals living with debilitating chronic conditions, like Parkinson’s, without them having to leave their homes is vitally important in today’s world,” said Drew Falconer, M.D., Director of the Parkinson’s and Movement Disorders Center, Inova Health System in Virginia. “Abbott’s NeuroSphere Digital Care solution, including the new Patient Controller app, allows patients to handle one single device and using the FaceTime application, interact with their provider teams in a convenient, easy-to-use interface — an important attribute for those with tremors or have challenges with mobility.”

The Patient Controller app will be integrated into Abbott’s broader NeuroSphere Digital Care connected care management platform, which became available in May. It is compatible with Abbott’s suite of neuromodulation technologies, including Infinity™ DBS System for patients with Parkinson’s disease or essential tremor, Proclaim™ XR SCS System for patients living with chronic pain, and Proclaim™ DRG Neurostimulation System for patients with chronic pain in the lower limbs caused by complex regional pain syndrome or causalgia. This integration across all Abbott neuromodulation technologies allows physicians to more easily treat the individual needs of each patient within their practice who have an Abbott device and Apple smartphone.

“Patients are seeking digital options to better engage with their healthcare providers and manage their chronic conditions remotely – and this has never been more evident than in today’s pandemic where virtual care is necessary,” said Keith Boettiger, vice president, Neuromodulation, Abbott. “With the continuing rise in interest and demand for these technologies, Abbott, as a pioneer in patient-centric neuromodulation technology, is advancing the field of digital health to deliver on the promise of digital care. The approval of Abbott’s Patient Controller app with personalized access to therapy is a landmark event, as we are now able to provide patients a way to access personalized therapy from a compatible and secure iOS device so that people can live their lives and seamlessly manage conditions like chronic pain and movement disorders.”

The Patient Controller app with personalized access to therapy will be made available starting in the coming weeks. For important safety information please visit the websites for Infinity DBS, Proclaim XR and Proclaim DRG devices.

About Abbott
Abbott is a global healthcare leader that helps people live more fully at all stages of life. Our portfolio of life-changing technologies spans the spectrum of healthcare, with leading businesses and products in diagnostics, medical devices, nutritionals and branded generic medicines. Our 107,000 colleagues serve people in more than 160 countries.

SIGNET Opens Network Operations Center to Offer Continuous Monitoring of Clients’ Mission Critical Technology Systems

SIGNET Opens Network Operations Center for Mission Critical Technology Systems

SIGNET Electronic Systems (SIGNET), the leading independent provider of technology solutions to healthcare organizations, municipalities and academic institutions throughout New England, announced the opening of its new next generation network operations center (NOC), known as SIGNET Remote Smart. Fully staffed with mission critical technology experts, Remote Smart is located at the company’s Norwell, Massachusetts, headquarters.

Traditionally, NOCs have only reacted to system faults and degradations, with a focus on minimizing their reaction and recovery time to technology incidents. Neither integrators nor NOC providers have been able to deploy predictive capabilities due to the significant technical challenges associated with disparate systems, the complexity of network technology and the speed of analytical processing required to make it work.

As a next generation network operations center, Remote Smart is different: we have the remote monitoring smarts and technology needed to proactively predict degradations rather than passively react to them. This enables us to fix problems before clients are even aware of them – or avoid them altogether – thereby improving the client experience and reducing churn. Applying our remote monitoring expertise helps ensure our clients’ maximum return on their mission critical technology while minimizing their total cost of ownership over time.

“A significant benefit of Remote Smart is the peace of mind it will give our clients,” said SIGNET President Brad Caron, “They no longer have to determine outages and report them. We know about any problems, and we know about them early. Since these kinds of issues typically escalate over time, it’s important to be made aware of them as soon as they arise.”

SIGNET is one of a select few ISO 9000-certified technology solution providers with a dedicated network operations center committed to mission critical solutions.

About SIGNET

Founded in 1974, SIGNET Electronic Systems Inc. has grown from a one-person installation services contractor to a 160-person complete technology solutions provider. From design, engineering and installation of a fully independent critical technology system to remote monitoring services, SIGNET delivers comprehensive technology expertise in the areas of life safety, communications, security, healthcare communications, audio visual, wireless connectivity, mission critical technologies program management and service.

Baxter and VIPUN Medical Announce Collaboration to Innovative Gastric Monitoring System to Help Enhance Clinical Nutrition

Baxter International Inc., a global leader in clinical nutrition, and VIPUN Medical, a company developing technology solutions to help improve medical nutrition, announced an agreement to commercialize the VIPUN Gastric Monitoring System. This innovative system features a “smart” enteral feeding tube designed to measure stomach motility in order to help clinicians identify enteral feeding intolerance and make better informed nutrition therapy decisions in the intensive care unit (ICU) and other settings. As part of the agreement, Baxter will support clinical studies required to achieve regulatory approval in key markets worldwide and gain global distribution rights. Additional terms of the agreement were not disclosed.

“The VIPUN Gastric Monitoring System will be an important addition to Baxter’s nutrition portfolio,” said Jorge Vasseur, general manager of Baxter’s Clinical Nutrition business. “While indirect calorimetry can help determine individual energy requirements, the VIPUN Gastric Monitoring System is designed to help address the need for accurate, real-time detection of tolerance to enteral feeding. For patients intolerant to enteral nutrition, our broad portfolio of parenteral nutrition products is available to help ensure they get the nutrients they need.”

Enteral feeding intolerance (EFI) is a serious problem among patients in the ICU. Approximately four in 10 patients in the ICU will experience EFI, which often leads to inadequate amounts of nutrition delivered to the patient and contributes to their malnutrition risk.1,2 EFI is associated with negative clinical outcomes like pneumonia, longer length of hospital stay and higher mortality rate.3,4 Diagnosis, treatment and monitoring of EFI are difficult as they require the evaluation of multiple clinical signs and symptoms, some of which are subjective and controversial, time consuming for clinicians, and vary between clinicians and centers.3 For patients who cannot tolerate enteral nutrition, parenteral nutrition may be the treatment modality used to reach nutrition targets.

“This innovative technology has the potential to significantly change the way clinicians provide nutrition therapy and directly enhance care of the most vulnerable patients,” said Nico Van Tichelen, CEO of VIPUN Medical. “In Baxter, we have found a partner who shares our commitment to helping to improve the practice of medical nutrition as well as the resources and expertise to make this technology available to clinicians and patients who need it most.”

About Baxter
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.

About VIPUN Medical
VIPUN Medical is a privately-owned spin-off company of KU Leuven, pioneering a novel method of gastro-intestinal monitoring aimed at enhancing medical nutrition for critically ill and other vulnerable patients. The VIPUN™ Gastric Monitoring System aims to make it easy for medical staff to make a well-informed and faster nutrition therapy decision thus reducing malnutrition and feeding-related complications. VIPUN Medical is located in Mechelen, Belgium.

1...585586587...1,125Page 586 of 1,125

About us

Hospital & healthcare Management is a leading B2B arena designed for the healthcare sector, it allow members to reach both ends of the healthcare facility procurement chain. . . Read More

Subscribe us

System

Resources

Archive Links

Subscribe

Copyright © 2008 - 2026 Hospital & Healthcare Management. All rights reserved. Publication of Leo Marcom Pvt Ltd.

Translate »